Patents Assigned to Alliance Pharmaceuticals Corp.
-
Patent number: 5437272Abstract: Method and means for maintaining respiratory gas exchange, by introducing into the pulmonary air passages of a mammalian host a volume of perfluorocarbon liquid substantially equivalent to the pulmonary functional residual capacity of the host, maintaining respiratory gas exchange in the perfluorocarbon liquid-laden pulmonary air passages by continuous positive pressure breathing with a conventional respirator, for up to an hour or more, and thereafter evaporating the perfluorocarbon liquid from the pulmonary air passages. Useful for treating pulmonary surfactant deficiency or dysfunction.Type: GrantFiled: May 1, 1991Date of Patent: August 1, 1995Assignee: Alliance Pharmaceutical Corp.Inventor: Bradley P. Fuhrman
-
Patent number: 5414358Abstract: A method for improving fat saturation during magnetic resonance imaging (MRI) by placing a fat saturation enhancing material such as a fluorocarbon, preferably perfluorooctylbromide, perfluorodecylbromide, FC-77, or FC-43, on or around a part of the body of a patient to be scanned with MRI, thereby eliminating the skin-air interface and reducing anatomical imaging problems, wherein the placement of the fat saturation enhancing material may be accomplished by enclosing the fat saturation enhancing material in a container which may also contain the MRI coil.Type: GrantFiled: August 5, 1993Date of Patent: May 9, 1995Assignee: Alliance Pharmaceutical Corp.Inventors: Steven S. Eilenberg, Jack DeFranco, Mark Walters, W. Dean Kirkland
-
Patent number: 5393513Abstract: A non-toxic, brominated perfluorocarbon emulsion for internal and intravenous use in animals (including humans) is disclosed, for use as an oxygen transport medium and as a contrast enhancement medium capable of facilitating the detection of tumors and other elements within the body. This emulsion is stable and maintains its very small particle size characteristics for extended periods of time, often exceeding eighteen months after sterilization, and further may include a stabilizing component selected from the group consisting of steroids, tocopherols, cholesterols, and combinations thereof. An anti-oxidizing component enhances delivery in oxygen transport.Type: GrantFiled: July 30, 1993Date of Patent: February 28, 1995Assignee: Alliance Pharmaceutical Corp.Inventor: David M. Long, Jr.
-
Patent number: 5344930Abstract: Compounds of the general formula: ##STR1## are useful as surfactants in the preparation of fluorocarbon emulsions, which can be used as oxygen-carrying blood substitutes, and for many other therapeutic and diagnostic applications. They are further useful in liposomal formulations which are themselves therapeutic agents or provide a vehicle for such agents.Type: GrantFiled: November 8, 1993Date of Patent: September 6, 1994Assignee: Alliance Pharmaceutical Corp.Inventors: Jean G. Riess, Francois Jeanneaux, Marie-Pierre Krafft, Catherine Santaella, Pierre Vierling
-
Patent number: 5344393Abstract: A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of removing and preferably storing a portion of the patient's blood, intravenously administering a biocompatible liquid in sufficient quantity to substantially maintain the patient's hemodynamic stability, wherein the liquid comprises an effective oxygen-delivery enhancing amount of a biocompatible synthetic oxygen carrier, after which the patient undergoes a loss of blood, and then readministering blood to the patient, preferably the stored blood. In one embodiment, the biocompatible liquid further comprises a hemodiluent and the hemodiluent is administered separately from the oxygen carrier.Type: GrantFiled: February 28, 1992Date of Patent: September 6, 1994Assignee: Alliance Pharmaceutical Corp.Inventors: Duane J. Roth, Peter E. Keipert, Nicholas S. Faithfull, Thomas F. Zuck, Jean G. Riess
-
Patent number: 5339033Abstract: A method for improving fat saturation during magnetic resonance imaging (MRI) by placing a fat saturation enhancing material such as a fluorocarbon, preferably perfluorooctylbromide, perfluorodecylbromide, FC-77, or FC-43, on or around a part of the body of a patient to be scanned with MRI, thereby eliminating the skin-air interface and reducing anatomical imaging problems, wherein the placement of the fat saturation enhancing material is accomplished by containing the fat saturation enhancing material in a bag.Type: GrantFiled: August 11, 1992Date of Patent: August 16, 1994Assignee: Alliance Pharmaceutical Corp.Inventors: Steven S. Eilenberg, W. Dean Kirkland, Mark A. Walters
-
Patent number: 5284645Abstract: Disclosed are fluorocarbon emulsions comprising amino acids and substances related to amino acids, such as substituted amino acids or amphoteric groups of amino acid side chains, for example, the imidazolyl group of histidine. Emulsion formulations comprising imidazole and imidazole based drugs possess anti-inflammatory and antipyretic properties which counteract transient inflammatory responses which occur when these emulsions are administered in vivo. Lipid constituents of histidine-containing emulsions are protected against oxidation caused by free radical formation.Disclosed also are emulsion formulations buffered with amino acids comprising histidine, imidazole, and related compounds that have a buffering capacity sufficient to maintain the emulsion pH within a specified range under storage conditions and protect these emulsions from the endogenous production of acid.Type: GrantFiled: October 4, 1989Date of Patent: February 8, 1994Assignee: Alliance Pharmaceutical Corp.Inventor: David M. Long, Jr.
-
Patent number: 5281582Abstract: A novel glycosylated form of albumin designated EGA and isolated from biological fluids is further characterized by its cell growth promoting activity. A process of isolation of human or bovine glycosylated albumin is described. The EGA fractions have been identified by serological histochemical and biological assays as well as lectin reactivity. The growth-promoting effect of EGA is directed to various transformed cell lines and primary cells of mammalian origin. Hepatoma cells have been found to produce EGA, in vitro. Novel compositions of EGA containing media are provided for cell, tissue or organ culture.Type: GrantFiled: February 27, 1992Date of Patent: January 25, 1994Assignee: Alliance Pharmaceuticals, Corp.Inventor: Philip Dehazya
-
Patent number: 5114703Abstract: Injectable contrast agents of great clinical importance for lymphography, characterized by non-water soluble particle sizes between about 5 or 10 nm and about 500 or 900 nm, which have selective distribution to lymph nodes upon percutaneous administration and can be imaged with millimeter resolution. Also disclosed are methods for performing percutaneous lymphography using these contrast agents.Type: GrantFiled: May 29, 1990Date of Patent: May 19, 1992Assignee: Alliance Pharmaceutical Corp.Inventors: Gerald L. Wolf, David M. Long
-
Patent number: 5080885Abstract: A non-toxic, brominated perfluorocarbon emulsion for internal and intravenous use in animals (including humans) is disclosed, for use as an oxygen transport medium and as a contrast enhancement medium capable of facilitating the detection of tumors and other elements within the body. This emulsion is stable and maintains its very small particle size characteristics for extended periods of time, often exceeding eighteen months after sterilization, and further may include a stabilizing component selected from the group consisting of steroids, tocopherols, cholesterols, and combinations thereof. An anti-oxidizing component enhances delivery in oxygen transport.Type: GrantFiled: August 24, 1989Date of Patent: January 14, 1992Assignee: Alliance Pharmaceutical Corp.Inventor: David M. Long, Jr.
-
Patent number: 5077036Abstract: Biocompatible fluorcarbon emulsions having fluorocarbon in concentrations of from 75% weight per volume to 125% weight per volume have small, biocompatible particle size stability through heat sterilization with one emulsifying agent, including phospholipids, in concentrations of from 3% to 7% weight per volume. The single emulsifying agent can be hydrogenated lecithins and synthesized lecithins. Fluorocarbon emulsions having fluorocarbon in concentrations of from 40% weight per volume to 125% weight per volume have stability of partial pressure of oxygen and of partial pressure of carbon dioxide through heat sterilization and storage for extended periods of time after having been oxygenated with dissolved oxygen.Type: GrantFiled: March 30, 1990Date of Patent: December 31, 1991Assignee: Alliance Pharmaceutical Corp.Inventor: David M. Long, Jr.
-
Patent number: 4993415Abstract: Perfluorocarbon hydrides, either alone or in combination with other perfluorocarbon compounds, may be introduced into a non-vascular animal space as a contrast agent in magnetic resonance imaging (MRI), computed tomography (CT) or conventional x-ray procedures. In the image generated by these systems, the fluorocarbon introduced into the space is contrasted with the remaining body tissues or spaces to distinguish the fluorocarbon-occupied space from other tissues and spaces.Perfluoroctyl hydride vaporizes at body temperature, and its gas phase, which also provides in effective contrast to tissues, is disclosed in imaging areas of comparatively large void volume while using a lower fluorocarbon dose then than required for fluid fluorocarbon.Perfluorocarbon hydrides offer less radiodensity to x-ray imaging and less hydrogen density to MRI imaging, and are disclosed as diluents for perfluorocarbon bromides in applications where concentrated brominated compounds are found to cause imaging artifacts.Type: GrantFiled: July 12, 1990Date of Patent: February 19, 1991Assignee: Alliance Pharmaceutical Corp.Inventor: David M. Long
-
Patent number: 4987154Abstract: An up to 125% fluorocarbon emulsion for use in or with animal bodies and organs thereof, maintains emulsion stability through normal sterilization procedures with selective osmotic and buffering agents, maintains the emulsion at within predetermined osmolarity levels and, when desired, free of excessive calcium precipitation, reduces in vivo and in vitro red blood cell injury, reduces adverse anemia effects, reduces viscosity and reduces the rate of oxidation, and tends to equilibrate its distribution in major body organs thereby reducing toxicity. The osmotic agents may buffer and may provide nutrient in the form of sugars.Type: GrantFiled: August 5, 1987Date of Patent: January 22, 1991Assignee: Alliance Pharmaceutical Corp.Inventor: David M. Long, Jr.
-
Patent number: 4985550Abstract: Compounds having a polyhydroxylated hydrophilic moiety, a highly fluorinated moiety and a functional junction group linking said moieties together, wherein said hydrophilic moiety is derived from a polyol or an aminopolyol, and wherein said highly fluorinated moiety consists of a fluorocarbon group wherein at lest 50% of the atoms bonded to the carbon skeleton are fluorine atoms, the other atoms bonded to the carbon skeleton being hydrogen, chlorine or bromine atoms, said highly fluorinated moiety containing at least 4 fluorine atoms; as well as the internal ethers and ketals thereof; process for their preparation; and a compositions containing said compounds as surfactants, together with non polar compounds, for use as gas carriers.Type: GrantFiled: July 28, 1987Date of Patent: January 15, 1991Assignee: Alliance Pharmaceutical Corp.Inventors: Brigitte Charpiot, Jacques Greiner, Maurice Le Blanc, Alexandre Manfredi, Jean Riess, Leila Zarif
-
Patent number: 4951673Abstract: Perfluorocarbon hydrides, either alone or in combination with other perfluorocarbon compounds, may be introduced into a non-vascular animal space as a contrast agent in magnetic resonance imaging (MRI), computed tomography (CT) or conventional x-ray procedures. In the image generated by these systems, the fluorocarbon introduced into the space is contrasted with the remaining body tissues or spaces to distinguish the fluorocarbon-occupied space from other tissues and spaces. Perfluoroctyl hydride vaporizes at body temperature, and its gas phase, which also provides an effective contrast to tissues, is disclosed in imaging areas of comparatively large void volume while using a lower fluorocarbon dose then than required for fluid fluorocarbon. Perfluorocarbon hydrides offer less radiodensity to x-ray imaging and less hydrogen density to MRI imaging, and are disclosed as diluents for perfluorocarbon bromides in applications where concentrated brominated compounds are found to cause imaging artifacts.Type: GrantFiled: August 19, 1988Date of Patent: August 28, 1990Assignee: Alliance Pharmaceutical Corp.Inventor: David M. Long
-
Patent number: 4927623Abstract: Biocompatible fluorocarbon emulsions having fluorocarbon in concentrations of from 75% weight per volume to 125% weight per volume have small, biocompatible particle size stability through heat sterilization with one emulsifying agent, including phospholipids, in concentrations of from 3% to 7% weight per volume. The single emulsifying agent can be hydrogenated lecithins and synthesized lecithins. Fluorocarbon emulsions having fluorocarbon in concentrations of from 40% weight per volume to 125% weight per volume have stability of partial pressure of oxygen and of partial pressure of carbon dioxide through heat sterilization and storage for extended periods of time after having been oxygenated with dissolved oxygen.Type: GrantFiled: January 4, 1988Date of Patent: May 22, 1990Assignee: Alliance Pharmaceutical Corp.Inventor: David M. Long, Jr.